Movement Disorders最新文献

{"title":"Long-Duration Response to Levodopa in the PPMI-Cohort","authors":"Nils Schnalke MD,&nbsp;Tim Feige,&nbsp;Tom Hähnel MD,&nbsp;Björn Falkenburger MD","doi":"10.1002/mds.70344","DOIUrl":"10.1002/mds.70344","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Treatment of Parkinson's disease (PD) with levodopa results in a sustained reduction of symptoms. Although the plasma half-life of levodopa is short, it elicits a lasting effect, the long-duration levodopa response (LDR). A decrease in LDR as PD progresses has been linked to motor complications, but long-term data on the LDR and its clinical implications remain scarce.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The aim is to analyze the magnitude and impact of the LDR over time using data from the Parkinson's Disease Progression Marker Initiative (PPMI).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>First, therapy-naïve Movement Disorder Society-Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS III) scores were predicted using a mixed linear model (MLM) from n = 245 untreated people with PD (PwPD). This model yielded an increase of MDS-UPDRS III scores of 2.65 points per year. Using this model, we then calculated LDR and short-duration response in longitudinal data of 148 initially therapy-naïve PwPD. Symptom progression was analyzed using correlation analyses and MLMs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the 98 PwPD with observed LDR, the LDR accounted for approximately half of the total levodopa response. No significant change in LDR magnitude was observed over up to 10 years (analysis of variance, <i>P</i> = 0.14; generalized estimating equations, <i>P</i> = 0.26). The LDR magnitude was not associated with the onset of motor complications. PwPD with absent LDR (n = 50) progressed faster than PwPD with observed LDR in several motor and non-motor domains.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The LDR is a stable component of the levodopa response and needs to be considered in clinical trials. These findings argue against a declining LDR as a major driver of motor fluctuations in PD. © 2026 The Author(s). <i>Movement Disorders</i> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>\u0000 </section>\u0000 </div>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"2033-2041"},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.70344","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147864137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Movement Disorders: Volume 41, Number 8, August 2026","authors":"","doi":"10.1002/mds.70460","DOIUrl":"https://doi.org/10.1002/mds.70460","url":null,"abstract":"","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.70460","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148816643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Speech and Deep Brain Stimulation in Parkinson's Disease, Essential Tremor, and Dystonia: A Systematic Review and Meta-analysis","authors":"Elina Tripoliti PhD,&nbsp;Takashi Tsuboi MD, PhD,&nbsp;Michael T. Barbe MD, PhD,&nbsp;Mario Sousa MD,&nbsp;Julie Barkmeier-Kraemer PhD,&nbsp;Hannah Jergas MD, PhD,&nbsp;Gaia Arno BSc,&nbsp;Nicole Buie BSc,&nbsp;Mikayla Day BSc,&nbsp;Petr Krýže MSc,&nbsp;Jayson R. Nelson BSc,&nbsp;Aaron E.L. Warren PhD,&nbsp;Shervin Rahimpour MD,&nbsp;Jan Rusz PhD,&nbsp;Paul Krack MD, PhD,&nbsp;Kristina Simonyan MD, PhD, DrMed","doi":"10.1002/mds.70322","DOIUrl":"10.1002/mds.70322","url":null,"abstract":"<p>Deep brain stimulation (DBS) effectively treats motor symptoms in movement disorders but often compromises speech through incompletely defined mechanisms. We conducted a PROSPERO-registered systematic review and meta-analysis of publications through August 2024 (CRD42024527738). Among 2726 screened records, we included 184 studies: 131 in Parkinson's disease (PD), 32 in essential tremor (ET), and 21 in dystonia, assessing perceptual, acoustic, and patient-reported speech outcomes. Meta-analyses showed that subthalamic nucleus DBS in PD resulted in poorer speech intelligibility compared with best medical treatment (effect size −0.24; 95% confidence interval: −0.46 to −0.03; <i>P</i> = 0.027), with state-dependent decline under active stimulation on longitudinal analysis (Unified Parkinson's Disease Rating Scale Part III item 18 monthly change: medication <i>on</i> +0.016, <i>P</i> &lt; 0.001; medication <i>off</i> +0.002, <i>P</i> = 0.50). In ET, DBS consistently suppressed vocal tremor but increased the risk of dysarthria, particularly with bilateral stimulation. Dystonia outcomes showed greater heterogeneity. Across disorders, sustained phonation measures improved, whereas connected speech performance worsened, indicating selective vulnerability of complex motor tasks. Neuroanatomical mapping identified two nonexclusive mechanisms: current spread to corticobulbar fibers producing spastic speech features and to the cerebellothalamocortical pathway producing ataxic features. Hypokinetic and stuttering-like phenotypes also occurred but likely reflect network-level interactions rather than tract-specific spread. These tract-mediated and network-level alterations appear to interact with hemispheric lateralization, medication state, and longer-term plasticity to produce complex clinical phenotypes. We outline a clinical framework integrating systematic screening, phenotype identification, and targeted programming adjustments. Enhanced speech assessment, precise field mapping, and adaptive DBS paradigms may promote individualized care that optimizes speech and motor function in precision DBS therapy. © 2026 The Author(s). <i>Movement Disorders</i> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"1928-1978"},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.70322","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147795580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progression of Motor and Cognitive Functions in Isolated REM Sleep Behavior Disorder: A 7-Year Prospective Matched Cohort Study","authors":"Li Zhou MD, PhD,&nbsp;Yaping Liu MD, PhD,&nbsp;Bei Huang MD, PhD,&nbsp;Jing Wang MD, PhD,&nbsp;Shi Tang MD, PhD,&nbsp;Yuhua Yang MD, PhD,&nbsp;Siyi Gong MD, PhD,&nbsp;Steven W.H. Chau FHKAM (Psych),&nbsp;Joey W.Y. Chan FHKAM (Psych),&nbsp;Mandy W.M. Yu MPH, RPSGT,&nbsp;Jessie C.C. Tsang RN,&nbsp;Shirley Xin Li PhD, DClinPsy,&nbsp;Siu Ping Lam FHKAM (Psych),&nbsp;Vincent C.T. Mok MD, FRCP,&nbsp;Karen K.Y. Ma MD,&nbsp;Anne Y.Y. Chan MD,&nbsp;Jihui Zhang MD, PhD,&nbsp;Yun Kwok Wing FRCPsych","doi":"10.1002/mds.70346","DOIUrl":"10.1002/mds.70346","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Although clinical markers (eg, motor and cognitive impairment) in isolated rapid eye movement sleep behavior disorder (iRBD) are associated with faster phenoconversion, their longitudinal trajectory patterns (linear or nonlinear) remain unclear. Additionally, evidence regarding the magnitude of neurodegenerative risk in iRBD compared to non-RBD individuals remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The aim was to investigate longitudinal changes in clinical markers and assess the magnitude of neurodegenerative risk in iRBD versus non-RBD subjects.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this prospective matched cohort study, video-polysomnography-confirmed iRBD patients and age- and sex-matched non-RBD subjects were followed every 1.5–2 years to evaluate neurodegenerative outcomes and markers. Longitudinal marker changes and neurodegenerative risk between groups were compared.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>One-hundred thirty-three iRBD patients and 101 non-RBD subjects were followed for a mean of 6.9 ± 2.9 years. Parkinsonism-first converters were associated with motor dysfunction, whereas dementia-first converters were associated with cognitive, motor, olfactory, and color vision dysfunctions. Motor and global cognitive functions exhibited nonlinear progression in iRBD, with marked acceleration before parkinsonism or dementia diagnosis. Conversion rates in iRBD patients were 4.7% at 3 years, 30.1% at 7 years, and 79.5% at 13 years, exceeding those in non-RBD subjects (3% at 3 years and 16.1% at 13 years). iRBD patients had a higher neurodegeneration risk (hazard ratio [95% confidence interval [CI]: 9.6 [3.8, 23.8], <i>P</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Motor and global cognition demonstrate nonlinear accelerating progressions during iRBD phenoconversion. iRBD carries a nearly 10-fold higher risk of future neurodegeneration than non-RBD subjects. These findings highlighted a critical window for risk stratification and early intervention before neurodegenerative disease onset in iRBD. © 2026 The Author(s). <i>Movement Disorders</i> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>\u0000 </section>\u0000 </div>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"2086-2095"},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.70346","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147826304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogenous Neuropathology in a Pedigree with RAB39B-Related Parkinson's Disease","authors":"Caitlin Latimer MD, PhD,&nbsp;Oswaldo Lorenzo-Betancor MD, PhD,&nbsp;Dong-Hui Chen MD, PhD,&nbsp;Kimmy Su MD, PhD,&nbsp;Marika Bogdani MD, PhD,&nbsp;Anna J. Park BS,&nbsp;Minsuh Kim BS,&nbsp;Joshua Weiss BS,&nbsp;Malia Callier HS,&nbsp;Ella H. Chiu HS,&nbsp;Sarah Fish BS,&nbsp;Jennifer L. Witt MD,&nbsp;Wendy H. Raskind MD, PhD,&nbsp;Marie Y. Davis MD, PhD,&nbsp;C. Dirk Keene MD, PhD,&nbsp;Cyrus P. Zabetian MD, MS","doi":"10.1002/mds.70341","DOIUrl":"10.1002/mds.70341","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In 2015, we reported a family with Parkinson's disease resulting from the RAB39B p.G192R (c.574G&gt;A) variant. Since then, two affected brothers from the family have undergone autopsy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To characterize neuropathological findings, assess intracellular distribution of RAB39B protein, and examine the effect of p.G192R on <i>α</i>-synuclein and tau.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Detailed neuropathological assessments were performed on both siblings. Dopaminergic neurons were generated from induced pluripotent stem cells (iPSCs) from an affected and unaffected male in this kindred. Western blots were performed to measure RAB39B, <i>α</i>-synuclein, phospho-<i>α</i>-synuclein, and phospho-tau.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The younger brother had neocortical stage Lewy body disease (LBD) pathology and an unusual pattern and burden of four-repeat (4R) tau pathology that included neocortical neurofibrillary tangles, pretangles, and neurites in the absence of <i>β</i>-amyloid pathology. The older brother's brain showed a similar pattern of 4R tau pathology but had no LBD pathology. Robust RAB39B immunostaining was seen in p.G192R carriers and non-carriers. In p.G192R iPSC-derived neurons, RAB39B protein was reduced by ~50% and disproportionately diminished in peripheral cell processes compared with cell bodies. Aberrant forms of both <i>α</i>-synuclein and tau were observed in p.G192R neurons.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The intrafamilial pathological heterogeneity observed here is unusual for monogenic parkinsonism and suggests that mechanisms underlying RAB39B-related neurodegeneration might be complex. Our results from iPSC-neurons provide additional support that RAB39B p.G192R promotes <i>α</i>-synuclein and tau co-pathology. Further work in model systems based on RAB39B p.G192R might offer important insights into the interplay between <i>α</i>-synuclein and tau that are applicable to multiple neurodegenerative disorders. © 2026 The Author(s). <i>Movement Disorders</i> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.</p>\u0000 </section>\u0000 </div>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"2096-2106"},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.70341","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147944468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Dark Matter of Levodopa Pharmacodynamics","authors":"Roger L. Albin MD,&nbsp;Daniel K. Leventhal MD, PhD,&nbsp;Philipp Mahlknecht MD, PhD","doi":"10.1002/mds.70372","DOIUrl":"10.1002/mds.70372","url":null,"abstract":"","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"1924-1927"},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148039230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co- and Multi-Pathologies in Parkinson's Disease: An International Parkinson and Movement Disorder Society Scientific Issues Committee Review","authors":"Michele Matarazzo MD,&nbsp;Per Borghammer MD, PhD, DMSc,&nbsp;Inas Elsayed PhD,&nbsp;Jennifer G. Goldman MD, MS,&nbsp;Yue Huang MD, PhD,&nbsp;Katja Lohmann PhD,&nbsp;Per Svenningsson MD, PhD,&nbsp;Lorraine V. Kalia MD, PhD,&nbsp;Daniela Berg MD,&nbsp;Jeffrey H. Kordower PhD,&nbsp;the MDS Scientific Issues Committee","doi":"10.1002/mds.70324","DOIUrl":"10.1002/mds.70324","url":null,"abstract":"<p>Parkinson's disease (PD) has been historically defined as a disease of striatal dopamine deficiency secondary to degeneration of dopaminergic neurons in the substantia nigra pars compacta, related to the presence of Lewy bodies and Lewy neurites. Since the discovery of pathogenic variants in the gene encoding α-synuclein, as well as the finding that α-synuclein is a major constituent of Lewy pathology, PD is considered as a prototypical synucleinopathy. However, neuropathological studies consistently show that most people with PD display copathologies, many of which are linked to specific clinical features and outcomes. In this review, we summarize the spectrum and frequency of these co- and multi-pathologies in idiopathic and genetic PD and their impact on disease initiation and progression. Additionally, we also discuss how this multi-pathological landscape may impact biomarker research and the implementation of emerging disease-modifying therapies. © 2026 The Author(s). <i>Movement Disorders</i> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"1979-1992"},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.70324","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147990847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paradigm Shift in Surgery for Movement Disorders; Again?","authors":"Marwan Hariz MD, PhD,&nbsp;Patric Blomstedt MD, PhD","doi":"10.1002/mds.70370","DOIUrl":"10.1002/mds.70370","url":null,"abstract":"","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"2007-2011"},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148020056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aiming at the Seed: α-Synuclein Immunotherapy in Multiple System Atrophy","authors":"Akansha Jain DM,&nbsp;Sanjay Pandey DM","doi":"10.1002/mds.70430","DOIUrl":"10.1002/mds.70430","url":null,"abstract":"","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"2012-2013"},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148408046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qihuang Needle Therapy for Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial","authors":"Wanqing Peng MD,&nbsp;Renhui Zhao MM,&nbsp;Ziting Huang MM,&nbsp;Jingpei Zhou MD,&nbsp;Yanning Liu MM,&nbsp;Zhijuan Liu MM,&nbsp;Xinyu Li PhD,&nbsp;Jingjing Deng MM,&nbsp;Xubo Hong MM,&nbsp;Yanfang Chen MM,&nbsp;Nanbu Wang MD,&nbsp;Zhenhu Chen MD","doi":"10.1002/mds.70343","DOIUrl":"10.1002/mds.70343","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Motor symptoms in Parkinson's disease (PD) often respond incompletely to medication, highlighting the need for effective adjunctive therapies. Acupuncture may offer benefits, but high-quality evidence for specialized techniques such as Qihuang needle therapy is lacking.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Our goal was to evaluate the efficacy of Qihuang needle therapy for improving motor symptoms in PD patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This single-center, randomized, single-blind, sham-controlled trial, enrolled 140 patients with idiopathic PD, who were assigned to either Qihuang needle therapy or sham acupuncture for nine sessions over 6 weeks, in addition to their stable medications. The primary outcome was the change in the Unified Parkinson's Disease Rating Scale Part III (UPDRS-III) score from baseline to week 6. Secondary outcomes included changes in the Non-Motor Symptoms Scale (NMSS) and the 39-item Parkinson's Disease Questionnaire (PDQ-39).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 129 participants (92.1%) completed the trial. The Qihuang needle group showed significantly greater improvement in UPDRS-III at week 6 (between-group difference: 8.45 points; 95% confidence interval [CI], 5.49–11.42; <i>P</i> &lt; 0.001), sustained at 10-week follow-up (10.88 points; 95% CI, 7.89–13.87; <i>P</i> &lt; 0.001). Significant improvements were also noted in non-motor symptoms (NMSS) and quality of life (PDQ-39) at both time points (all <i>P</i> &lt; 0.001). Greatest efficacy was observed in postural instability and gait disorder subtypes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Qihuang needle therapy significantly improved motor and non-motor symptoms and quality of life in PD patients compared with that via sham acupuncture, with benefits sustained for ≥1 month. These findings support Qihuang needle therapy as a safe and effective adjunctive treatment for PD. © 2026 The Author(s). <i>Movement Disorders</i> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>\u0000 </section>\u0000 </div>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"2051-2061"},"PeriodicalIF":7.7,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.70343","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147864154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}